20 results about "HCV Positive" patented technology

The invention provides a medicine composition for treating cancer. The medicine composition comprises an inhibitor for inhibiting FOXRED2 protein expression and application of Paraprevir in preparation of a medicine for treating cancer. According to the application disclosed by the invention, the new indication of the hepatitis C medicine paritaprevir for inhibiting the malignant process of the liver cancer HCC is found for the first time, the treatment field of the medicine in the liver cancer is expanded, and a theoretical basis is provided for developing a new target spot for treating the liver cancer.

The present invention relates to a composition for detecting hepatitis C viruses HCV 4, HCV 1b, HCV 1, HCV 2 and HCV 3 and differentiating same, and the use thereof.

The present invention relates to novel macrocyclic compounds and methods of use thereof. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.

A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g., Compound 1-A) and Compound 2 or a pharmaceutically acceptable salt thereof, as well as its uses to treat hepatitis C or a condition related to hepatitis C, as well as methods for the manufacture of the pharmaceutical combination:

The application provides a hepatitis C antibody detection antigen composition and application, kit and detection method thereof, relates to the antibody detection technical field, and the hepatitis C antibody detection antigen composition comprises a labeled recombinant antigen and a coated recombinant antigen, the amino acid sequence of the labeled recombinant antigen includes Trx and hepatitis C Core region, NS3 protein, NS4b protein dominant epitope and His tag, and the full-length sequence is shown as SEQ ID NO. 1. The labeled recombinant antigen used in the application is obtained by mutating 7 cysteines (C) into alanine (A) by amino acid mutation on the NS3 protein, reducing the aggregation and precipitation caused by disulfide bond of the recombinant protein, and improving the protein stability. When colloidal gold is used for antigen labeling, a secondary indirect labeling method is adopted, which is beneficial to the exposure of antigen epitopes, can improve the reaction sensitivity, and reduces the antibody missed detection.

The invention belongs to the technical field of disease diagnosis and molecular biology, and particularly relates to application of LncRNA 02365 in HBV (Hepatitis B Virus) related HCC (Hepatitis C Chromatography) diagnosis. It is found for the first time that the LncRNA 02365 is abnormally high in expression in HBV-related HCC patients, the verification result of the serum-derived LncRNA 02365 and the verification result of the HBV-related HCC tissue are consistent, the sensitivity of the test result is high, and the specificity is good. Therefore, the LncRNA 02365 can be used as a molecular biomarker for diagnosing the HBV-related HCC, so that the disease risk of HBV-related HCC patients is predicted, high-risk groups are screened, and early and rapid non-invasive diagnosis is performed on the HBV-related HCC patients.

A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g., Compound 1-A) and Compound 2 or a pharmaceutically acceptable salt thereof, as well as its uses to treat hepatitis C or a condition related to hepatitis C, as well as methods for the manufacture of the pharmaceutical combination:

The application discloses a postpartum hepatitis C referral management system based on a mobile terminal and relates to the medical management field.The system comprises a medical communication module, a data entry module and an index preset module.The medical communication module is used for integrating the communication permission of the mobile terminal and providing a plurality of communication channels.The data entry module is used for periodically collecting and entering the liver function indexes, the hepatitis C virus load data and the emotional evaluation scores of puerpera through the medical communication module.The index preset module is used for presetting the benchmark feeding indexes of future periods according to a newborn growth model.The risk prediction module is used for collecting the data of the current period data entry module and the preset feeding indexes of the next period based on the risk prediction model.The risk coefficient of breastfeeding behavior is dynamically predicted by using the risk prediction model, the potential risks under different feeding schemes are quantitatively evaluated, the high-risk puerpera are early identified, the disease deterioration or the risk of mother-to-child transmission caused by delayed intervention is reduced, the human error is reduced, and the accuracy and response speed of postpartum hepatitis C management are improved.

The invention provides a hepatitis C antibody detection antigen composition and application thereof, a kit and a detection method, and relates to the technical field of antibody detection, the hepatitis C antibody detection antigen composition comprises a recombinant antigen for marking and a recombinant antigen for coating, the amino acid sequence of the recombinant antigen for marking comprises Trx and hepatitis C Core regions, NS3 protein, NS4b protein dominant epitopes and a His tag, and the full-length sequence is as shown in SEQ ID NO. 1. According to the recombinant antigen for marking, the NS3 protein is subjected to amino acid mutation to mutate seven cysteines (C) into alanine (A), aggregation and precipitation caused by disulfide bonds of the recombinant protein are reduced, and the protein stability is improved. When colloidal gold is labeled by the antigen, a secondary indirect labeling method is adopted, so that the exposure of antigen epitopes is facilitated, the reaction sensitivity can be improved, and the leakage detection of antibodies is reduced.

The utility model relates to a hepatitis C detection kit. The sampling part and the detection part are located in the box body, the sampling part comprises a capillary tube with oblique notches at the two ends, one end of the capillary tube can collect a detection sample, the other end of the capillary tube is inserted into a detection chamber with a vacuum cavity inside after collection is completed, and the detection sample is detected through detection test paper located in the detection chamber. According to the utility model, through the integrated design of collection and detection and the combination of the collection part and the detection part in the box body, the technical problem that the risk of leakage of samples carrying hepatitis C viruses is increased due to multiple steps and independent operation in the traditional hepatitis C detection process is solved.

The present invention provides isolated nucleic acid molecules encoding Hepatitis C core and p7 proteins and an immunogen. Also provided are expression constructs, nucleic acid vectors, delivery vectors and host cells including the isolated nucleic acids. Further provided are methods of producing virus-like particles (VLPs) using the isolated nucleic acid molecules and VLPs produced by such methods. Also provided are the isolated nucleic acid molecules and VLPs or compositions thereof for use in vaccinating a subject in need thereof.

The present invention provides a simple and robust human liver cell-based system in which persistent hepatitis C infection, persistent hepatitis B infection or ethanol exposure induces a clinical Prognostic Liver Signature (PLS) high-risk gene signature. The cellular model system for hepatocellular carcinoma (HCC) / cirrhosis development and progression may be used in the screening of compounds useful in the treatment and / or prevention of cirrhosis and / or HCC as well as in the identification biomarkers for the prediction of liver disease (especially cirrhosis) progression and HCC. The present invention also relates to specific compounds that have been identified, using such screening methods, as useful in the treatment and / or the prevention of HCC / cirrhosis.

The utility model discloses a hepatitis C genetic typing detection experiment device which comprises a machine box, a transparent experiment box is fixed on one side of the machine box, ultraviolet sterilizing lamps are installed at the two ends inside the transparent experiment box respectively, operation openings are evenly formed in one side of the transparent experiment box, and the operation openings are connected with the machine box. A heat preservation storage groove and a PLC are mounted on one side, far away from the transparent experiment box, of the case. According to the utility model, the low-temperature storage cavity and the like are arranged; a user can respectively clamp a test tube filled with a hepatitis C genotyping detection reagent and some test tubes filled with samples to be detected into detection reagent storage grooves in the room-temperature storage cavities or the two low-temperature storage cavities with different temperatures according to the temperature requirements of a storage environment; and then the hepatitis C genotyping test paper is clamped into two test paper storage grooves in the room-temperature storage cavity for storage, so that the device has the advantage of classified storage, and experimental articles are convenient to store and flexible to take and use.

The present invention discloses an anti-HCV core antigen monoclonal antibody, a hybridoma cell line and their applications. Specifically, a hybridoma cell line screened against the common conserved sequence of the core proteins of different genotypes of HCV, and the antibody secreted by it is used in the detection of HCV antigens, which can detect hepatitis C viruses of different genotypes, has good inclusiveness, and only two antibodies are needed to achieve the above technical effects. This can not only reduce the production cost of HCV antigen detection kits, but also reduce the production difficulty and improve the production efficiency.

Chronic hepatitis C is a global health problem affecting large number of people and leads to mortalities and morbidities. In this invention, new compounds belonging to 2-substituted-1H-imidazole-4-carboxamide derivatives (Formula I) intended for use in the treatment of hepatitis C are disclosed. The compounds interfere with the important viral peptide NS4A co-enzyme function. The described art includes chemical synthesis, spectral confirmation and binding assays with NS3 protein.

A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g., Compound 1-A) and Compound 2 or a pharmaceutically acceptable salt thereof, as well as its uses to treat hepatitis C or a condition related to hepatitis C, as well as methods for the manufacture of the pharmaceutical combination:

The invention belongs to the technical field of nano-antibodies, and particularly relates to a nano-antibody for resisting galectin 3 binding protein as well as a preparation method and application of the nano-antibody. The galectin 3 binding protein is used as a research object, after being expressed and purified, the galectin 3 binding protein is used for immunizing alpaca, a phage display technology is used for screening to obtain the anti-galectin 3 binding protein nano antibody, and the antibody has high sensitivity and capacity of specifically binding with the galectin 3 binding protein. Through the preparation of the anti-galectin 3 binding protein nano antibody, a material is provided for establishing a diagnosis method for related diseases such as systemic lupus erythematosus, Behcet's disease, biliary tract cancer and hepatitis C.

The present invention addresses the problem of providing: a compound having a hepatitis C virus (HCV) inhibition activity and can prevent and / or treat hepatitis C; and a medicine containing the compound. [Solution] The present invention provides: a compound having a structure represented by formula (I) or (IV) and having an HCV inhibition activity; and a composition containing the compound.

The present application provides a composition for treating hepatitis C and a preparation method thereof. The composition comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The composition or capsule can effectively treat hepatitis C, and the preparation process is simple, safe, stable, and has rapid dissolution.

The present invention relates to a composition for detecting hepatitis C viruses HCV 4, HCV 1b, HCV 1, HCV 2 and HCV 3 and differentiating same, and the use thereof.